Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.614 USD | -28.03% | -38.60% | -56.14% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 5M | Capitalization | 92.99M |
---|---|---|---|---|---|
Net income 2024 * | -160M | Net income 2025 * | -146M | EV / Sales 2024 * | - |
Net Debt 2024 * | 126M | Net Debt 2025 * | 193M | EV / Sales 2025 * | 57.3 x |
P/E ratio 2024 * |
-0.59
x | P/E ratio 2025 * |
-0.86
x | Employees | 233 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.3% |
Latest transcript on Seres Therapeutics, Inc.
1 day | -28.03% | ||
1 week | -38.60% | ||
Current month | -38.60% | ||
1 month | -18.07% | ||
3 months | -36.73% | ||
6 months | -43.67% | ||
Current year | -56.14% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Shaff
CEO | Chief Executive Officer | 48 | 14-10-31 |
David Ege
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-10-21 |
Chief Tech/Sci/R&D Officer | - | 15-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 78 | 15-03-31 |
Director/Board Member | 68 | 23-01-03 | |
Richard Kender
BRD | Director/Board Member | 68 | 14-10-05 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 0 M€ | 0.00% | - | |
0.06% | 2 M€ | -.--% | ||
0.05% | 0 M€ | 0.00% | - | |
0.03% | 248 M€ | +11.05% | - | |
0.02% | 7 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 0.614 | -28.03% | 18,344,032 |
24-06-06 | 0.8531 | -25.17% | 14,082,675 |
24-06-05 | 1.14 | +6.54% | 3,597,022 |
24-06-04 | 1.07 | -0.93% | 2,925,963 |
24-06-03 | 1.08 | +8.00% | 1,840,376 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.14% | 92.99M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- MCRB Stock